Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vaxcyte, Inc. (PCVX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.00-0.18 (-0.41%)
At close: 01:00PM EST
44.20 +0.20 (+0.45%)
After hours: 04:27PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close44.18
Open44.08
Bid43.98 x 800
Ask44.06 x 800
Day's Range43.67 - 44.47
52 Week Range16.78 - 46.57
Volume156,054
Avg. Volume1,178,249
Market Cap2.323B
Beta (5Y Monthly)0.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

    -- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 18-64 -- -- Phase 1/2 Study Met Safety, Tolerability and Immunogenicity Objectives; Findings Indicate a Potential Best-in-Class Profile for VAX-24 -- -- Company Advancing VAX-24 in Adult and Pediatric Populations with Submission of Infant Investigational New Drug

  • GlobeNewswire

    Vaxcyte to Present at Upcoming Investor Conferences

    SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in and host one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology ConferenceNovember 14-15, 2022 Fireside Chat will take place live on Monday, November 14 at 1:35

  • GlobeNewswire

    Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 17,812,500 shares of common stock at a public offering price of $32.00 per share and pre-funded warrants to purchase 3,750,000 shares of common stock at a public offering price of $31

Advertisement
Advertisement